CTA
CRSP icon

Colonial Trust Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Colonial Trust Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4K Hold
209
– – ﹤0.01% 558
2026
Q1 		$9.94K Hold
209
– – ﹤0.01% 533
2025
Q4 		$11K Sell
209
-41
-16% -$2.46K ﹤0.01% 501
2025
Q3 		$16.2K Sell
250
-200
-44% -$11.5K ﹤0.01% 447
2025
Q2 		$21.9K Hold
450
– – ﹤0.01% 435
2025
Q1 		$15.3K Buy
450
+60
+15% +$2.54K ﹤0.01% 458
2024
Q4 		$15.3K Hold
390
– – ﹤0.01% 437
2024
Q3 		$18.3K Buy
390
+41
+12% +$2.08K ﹤0.01% 460
2024
Q2 		$18.8K Buy
349
+50
+17% +$2.89K ﹤0.01% 434
2024
Q1 		$20.4K Hold
299
– – ﹤0.01% 475
2023
Q4 		$18.7K Sell
299
-51
-15% -$2.82K ﹤0.01% 422
2023
Q3 		$15.9K Buy
350
+50
+17% +$2.58K ﹤0.01% 460
2023
Q2 		$16.8K Buy
300
+100
+50% +$5.67K ﹤0.01% 458
2023
Q1 		$9.05K Sell
200
-199
-50% -$9.66K ﹤0.01% 530
2022
Q4 		$16.2K Buy
+399
New +$21.2K ﹤0.01% 449

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Colonial Trust Advisors's CRSP Position: Q2 2026 in Review

Colonial Trust Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 209 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #558.

Colonial Trust Advisors first reported a position in CRSP in Q4 2022 and has held it in 15 quarters since. The position peaked at $21.9K in Q2 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Colonial Trust Advisors held 209 shares of CRISPR Therapeutics worth $11.4K as of Q2 2026.
  • Colonial Trust Advisors left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Colonial Trust Advisors's portfolio in Q2 2026, its #558 holding.
  • Colonial Trust Advisors first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Colonial Trust Advisors's CRISPR Therapeutics position peaked at $21.9K in Q2 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Colonial Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.